Showing results (11-20 of 331) with videos related to
Sort By:
Pageof 34
Frontiers in Immunology|July 29, 2021
Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?Denise C Hsu, John W Mellors, Sandhya VasanAnnual Review of Medicine|July 19, 2022
COVID-19: Challenges of Viral VariantsJana L Jacobs, Ghady Haidar, John W MellorsJournal of Virus Eradication|December 6, 2018
Regulatory T cells: the ultimate HIV reservoir?Joseph Rocco, John W Mellors, Bernard Jc MacatangayAntiviral Therapy|March 27, 2009
Simplification strategies to reduce antiretroviral drug exposure: progress and prospectsJohn E McKinnon, John W Mellors, Susan SwindellsJournal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settingsUme L Abbas, Roy M Anderson, John W MellorsCurrent HIV/AIDS Reports|September 16, 2022
Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?Urvi M Parikh, Catherine A Koss, John W MellorsJournal of Virology|November 13, 2015
HIV-1 Virion Production from Single Inducible Proviruses following T-Cell Activation Ex VivoJohn K Bui, John W Mellors, Anthony R CilloPlos One|September 20, 2007
Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settingsUme L Abbas, Roy M Anderson, John W MellorsBiochemistry|December 11, 2008
Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistanceJessica H Brehm, John W Mellors, Nicolas Sluis-CremerCurrent Opinion in HIV and AIDS|November 13, 2020
Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2Kevin D McCormick, John W Mellors, Jana L JacobsPageof 34